Gallium-68 PSMA-11 PET in Participants With Prostate Cancer
Phase 2
Withdrawn
- Conditions
- Recurrent Prostate CarcinomaStage IV Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Metastatic Prostate CarcinomaStage IVA Prostate Cancer AJCC v8
- Interventions
- Procedure: Computed TomographyDrug: Gallium Ga 68-labeled PSMA-11Procedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05034562
Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors
Early Phase 1
Recruiting
- Conditions
- Myeloid LeukemiaAcute Myeloid LeukemiaRecurrent Acute Myeloid Leukemia
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionOther: Electronic Health Record ReviewOther: Photography
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT05035706
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
Phase 2
Recruiting
- Conditions
- Breast CancerHER2-positive
- Interventions
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05035836
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase 1
Active, not recruiting
- Conditions
- Recurrent B Acute Lymphoblastic LeukemiaRefractory Lymphoblastic LymphomaRefractory B Acute Lymphoblastic LeukemiaRecurrent Adult Lymphoblastic LymphomaRefractory T Acute Lymphoblastic LeukemiaRecurrent T Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT05032183
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents
Phase 1
Completed
- Conditions
- Refractory Myelodysplastic SyndromeRefractory Chronic Myelomonocytic Leukemia
- Interventions
- First Posted Date
- 2021-09-01
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT05030675
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Feasibility of Digital Thermal Monitoring to Assess Endothelium-Dependent Vasodilation in Patients Undergoing Hematopoietic Cell Transplantation (HCT)
Not Applicable
Recruiting
- Conditions
- VascularEndothelialEndothelixEndothelial Dysfunction
- Interventions
- Device: Vendys II Device
- First Posted Date
- 2021-09-01
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT05029752
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
Phase 2
Recruiting
- Conditions
- the Nasal CavityParanasal SinusesSquamous Cell Carcinoma
- Interventions
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT05027633
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study
Phase 2
Active, not recruiting
- Conditions
- Metastatic AngiosarcomaRecurrent AngiosarcomaLocally Advanced Angiosarcoma
- Interventions
- Other: Quality-of-Life AssessmentBiological: Sintilimab
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT05026736
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
Phase 2
Recruiting
- Conditions
- Metastatic MelanomaPathologic Stage IV Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8
- Interventions
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT05026983
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
Phase 1
Recruiting
- Conditions
- Ann Arbor Stage III Marginal Zone LymphomaRefractory Follicular LymphomaAnn Arbor Stage III Grade 3 Follicular LymphomaRefractory High Grade B-Cell LymphomaRefractory Mantle Cell LymphomaAnn Arbor Stage III Grade 2 Follicular LymphomaAnn Arbor Stage IV Grade 3 Follicular LymphomaRefractory Aggressive B-Cell Non-Hodgkin LymphomaRefractory Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaAggressive B-Cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 47
- Registration Number
- NCT05025800
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath